Katrin Rupalla (Ymmunobio AG)

Rupalla, Katrin (Ymmunobio 202206 CEO)

	Organisation	Ymmunobio AG
	Product	CEACAM1 immune agonistic antibody
	Product 2	drug development

Ymmunobio AG. (6/16/22). "Press Release: Ymmunobio Signs Collaboration Agreement with Yumab". Riehen.

Ymmunobio to optimize its antibody development with YUMAB’s antibody technology Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM (carcinoembryonic antigen-related cell adhesion molecules) antibodies as anti-cancer treatments, today announced that it has signed a collaboration agreement with YUMAB GmbH, a privately-held German biotechnology company.

YUMAB provides technologies and contract research for the development of fully human antibodies for all therapeutic fields. Within the scope of the collaboration, Ymmunobio AG will complement its antibody development by utilizing YUMAB’s expertise and platform for optimizing its antibodies.

“We look forward to our collaboration being a productive complement to our capabilities,” said Dr. Katrin Rupalla, CEO, Ymmunobio AG. “Ymmunobio shares a commitment with YUMAB to accelerate drug development through antibody optimization.”

“We’re excited by the prospect of working with Ymmunobio to facilitate new pathways to antibody development,” said Dr. Thomas Schirrmann, YUMAB founder and CEO. “Ymmunobio shares our vision to accelerate drug discovery and ultimately improve patient outcomes.”

Ymmunobio is developing a proprietary class of CEACAM1 immune agonistic antibodies in order to employ the immune system to fight cancer. Financial conditions of the agreement were not disclosed.

Contact: Dr. Katrin Rupalla, info@ymmuno.bio

About YMMUNOBIO

Ymmunobio AG, a preclinical stage oncology biotech company, was founded by Dr. Katrin Rupalla and is committed to developing a proprietary class of CEACAM antibodies to increase the efficiency of the adaptive and innate immune system to fight cancer. Ymmunobio’s research targets defined CEACAM receptor isoforms that play a major role in the immune response and cancer cell evolution. The company’s proprietary platform is based on the leading research of Dr. Bernhard B. Singer, University Essen/Duisburg, Germany.

About YUMAB

YUMAB GmbH, a leading provider of contract research, technologies, and R&D services for the development of fully human, therapeutic antibodies, was founded in 2012 by scientists of the University of Braunschweig. A global player in human monoclonal antibody development, YUMAB is focused on the use of fully human antibodies for immunotherapies. For more information, please visit www.yumab.com.

Record changed: 2022-07-04

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for Katrin Rupalla

[1] Ymmunobio AG. (6/16/22). "Press Release: Ymmunobio Signs Collaboration Agreement with Yumab". Riehen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)